Chardan analyst Daniil Gataulin downgraded Clearside Biomedical (CLSD) to Neutral from Buy without a price target after the company said it will explore strategic alternatives. The firm awaits clarity on Clearside’s future plans.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical downgraded to Hold from Buy at Stifel
- Clearside Biomedical Downgraded to Hold Amid Strategic and Financial Uncertainties
- Needham downgrades Clearside on ‘disappointing’ decision to explore options
- Clearside Biomedical downgraded to Hold from Buy at Needham
- Clearside Biomedical downgraded to Hold from Buy at JonesResearch